Sepracor Estorra NDA Filing Planned By Mid-Feb.; Xopenex MDI By Year-End
Executive Summary
Sepracor is planning an NDA filing for its sleep disorder drug Estorra by Feb. 15, followed by a submission for its Xopenex metered dose inhaler formulation before year-end